share_log

Bionomics Analyst Ratings

Benzinga Analyst Ratings ·  Dec 20, 2022 05:07
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
12/20/2022 1.87% Evercore ISI Group $17 → $6 Downgrades Outperform → In-Line
12/19/2022 HC Wainwright & Co. Downgrades Buy → Neutral
11/01/2022 290.49% Loop Capital → $23 Initiates Coverage On → Buy
01/10/2022 782.85% Cantor Fitzgerald → $52 Initiates Coverage On → Overweight
01/10/2022 188.62% Evercore ISI Group → $17 Initiates Coverage On → Outperform
01/10/2022 256.54% Berenberg → $21 Initiates Coverage On → Buy

What is the target price for Bionomics (BNOX)?

The latest price target for Bionomics (NASDAQ: BNOX) was reported by Evercore ISI Group on December 20, 2022. The analyst firm set a price target for $6.00 expecting BNOX to rise to within 12 months (a possible 1.87% upside). 6 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Bionomics (BNOX)?

The latest analyst rating for Bionomics (NASDAQ: BNOX) was provided by Evercore ISI Group, and Bionomics downgraded their in-line rating.

When is the next analyst rating going to be posted or updated for Bionomics (BNOX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bionomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bionomics was filed on December 20, 2022 so you should expect the next rating to be made available sometime around December 20, 2023.

Is the Analyst Rating Bionomics (BNOX) correct?

While ratings are subjective and will change, the latest Bionomics (BNOX) rating was a downgraded with a price target of $17.00 to $6.00. The current price Bionomics (BNOX) is trading at is $5.89, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment